[
    {
        "Forest plot showing the risk ratios of RT-PCR-confirmed influenza among children who received adjuvanted versus non-adjuvanted trivalent vaccines or quadrivalent vaccines.": {
            "All-naive group": [
                "Vesikari et al., 2011",
                "Nolan et al., 2014"
            ],
            "Non-naive group": [
                "Vesikari et al., 2018"
            ]
        }
    },
    {
        "Forest plot showing the ratios of the seroprotection rate (SPR) against H1N1, defined as a \u22651:40 hemagglutinin inhibition (HI) titer, 21\u201328 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIVs) or quadrivalent vaccines (QIVs).": {
            "Poor response to non-adjuvanted TIV/QIV (SPR <25%)": [
                "Della Cioppa et al., 2011",
                "Vesikari et al., 2011",
                "Langley et al., 2012",
                "Diallo et al., 2018"
            ],
            "Moderate response to non-adjuvanted TIV/QIV (SPR 25% to 75%)": [
                "Vesikari et al., 2011",
                "Arguedas et al., 2011",
                "Block et al., 2012",
                "Nassim et al., 2012",
                "Knuf et al., 2015"
            ],
            "Good response to non-adjuvanted TIV/QIV (SPR >75%)": [
                "Vesikari et al., 2009",
                "Solares et al., 2014",
                "Vesikari et al., 2015",
                "Diallo et al., 2018"
            ]
        }
    },
    {
        "Forest plot showing the ratios of the seroprotection rate (SPR) against H3N2, defined as a \u22651:40 hemagglutinin inhibition (HI) titer, 21\u201328 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIVs) or quadrivalent vaccines (QIVs).": {
            "Poor response to non-adjuvanted TIV/QIV (SPR <25%)": [
                "Vesikari et al., 2011",
                "Della Cioppa et al., 2011",
                "Diallo et al., 2018"
            ],
            "Moderate response to non-adjuvanted TIV/QIV (SPR 25% to 75%)": [
                "Vesikari et al., 2011",
                "Solares et al., 2014",
                "Vesikari et al., 2015",
                "Diallo et al., 2018"
            ],
            "Good response to non-adjuvanted TIV/QIV (SPR >75%)": [
                "Solares et al., 2014",
                "Nolan et al., 2014",
                "Diallo et al., 2018"
            ]
        }
    },
    {
        "Forest plot showing the ratios of the seroprotection rate (SPR) against B, defined as a \u22651:40 hemagglutinin inhibition (HI) titer, 21\u201328 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIVs) or quadrivalent vaccines (QIVs).": {
            "Poor response to non-adjuvanted TIV/QIV (SPR <25%)": [
                "Della Cioppa et al., 2011",
                "Vesikari et al., 2011",
                "Solares et al., 2014"
            ],
            "Moderate response to non-adjuvanted TIV/QIV (SPR 25% to 75%)": [
                "Vesikari et al., 2011",
                "Solares et al., 2014",
                "Zedda et al., 2015"
            ],
            "Good response to non-adjuvanted TIV/QIV (SPR >75%)": [
                "Solares et al., 2014",
                "Nolan et al., 2014",
                "Diallo et al., 2018"
            ]
        }
    },
    {
        "Forest plot showing the risk ratios of serious adverse events during the follow-up time (ranging from 21 to 390 days) after the vaccinations among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIVs) or quadrivalent vaccines (QIVs).": {
            "Serious adverse events": [
                "Arguedas et al., 2011",
                "Block et al., 2012",
                "Cruz-Valdez et al., 2018",
                "Della Cioppa et al., 2011",
                "Diallo et al., 2018",
                "Langley et al., 2012",
                "Nassim et al., 2012",
                "Nolan et al., 2014",
                "Solares et al., 2014",
                "Vesikari et al., 2009",
                "Vesikari et al., 2011",
                "Vesikari et al., 2015",
                "Vesikari et al., 2018"
            ]
        }
    },
    {
        "Forest plot showing the risk ratios of neurological events during the follow-up time (ranging from 21 to 390 days) after the vaccinations among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIVs) or quadrivalent vaccines (QIVs).": {
            "Neurological events": [
                "Arguedas et al., 2011",
                "Cruz-Valdez et al., 2018",
                "Della Cioppa et al., 2011",
                "Diallo et al., 2018",
                "Knuf et al., 2015",
                "Nolan et al., 2014",
                "Solares et al., 2014",
                "Vesikari et al., 2009",
                "Vesikari et al., 2011",
                "Vesikari et al., 2015",
                "Vesikari et al., 2018",
                "Waddington et al., 2010",
                "Zedda et al., 2015"
            ]
        }
    }
]